Wegovy pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss
doi:10.2337/dc19-0883
Clinical trials show patients using Wegovy (semaglutide) lose average 15-20% of body weight over 12-18 months when combined with lifestyle modification, while Zepbound (tirzepatide) shows even greater results with average 20-25% body weight reduction in clinical studies
Some of the mechanisms through which semaglutide and tirzepatide lower blood sugar in type 2 diabetes are also likely to be relevant in type 1 diabetes, said study leader Janet Snell-Bergeon, MPH, PhD, of the University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
Alex Fishman, brand director at Pure Protein, added: As the dietary supplement market in the US becomes increasingly more congested and expensive, users and especially those taking GLP-1 medications are seeking simplified, yet effective solutions to help them achieve their health and fitness goals